Abstract
Background: Many studies have investigated the association between glutathione S-transferase T1 (GSTT1) null genotype and the risk of prostate cancer (PCa), but the impact of GSTT1 null genotype on PCa risk in Caucasians is still unclear owing to the inconsistency of such studies. The present study aimed to quantify the strength of association between GSTT1 null genotype and the risk of PCa in Caucasians. Methods: We searched the PubMed, Embase and Web of Science databases for studies assessing the association between GSTT1 null genotype and the risk of PCa in Caucasians. We estimated the summary odds ratio (OR) with the corresponding 95% confidence interval (95% CI) to assess the association. Results: 16 case-control studies with 11,648 subjects were included in this meta-analysis. Meta-analysis of a total of 16 studies showed GSTT1 null genotype was significantly associated with an increased risk of PCa in Caucasians (random-effects OR 1.30, 95% CI 1.10-1.53, p = 0.002). After adjustment for heterogeneity, GSTT1 null genotype was still associated with an increased risk of PCa in Caucasians (fixed-effects OR 1.33, 95% CI 1.17-1.52, p < 0.001). The cumulative meta-analyses of all 16 studies showed a trend of more obvious association as information accumulated by year. Conclusions: Meta-analysis of available data suggests the GSTT1 null genotype is significantly associated with an increased risk of PCa in Caucasians.
References
1.
Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2.
Damber JE, Aus G: Prostate cancer. Lancet 2008;371:1710-1721.
3.
Zhang L, Yang BX, Zhang HT, et al: Prostate cancer: an emerging threat to the health of aging men in Asia. Asian J Androl 2011;13:574-578.
4.
Brawley OW: Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200.
5.
Hoffman RM: Clinical practice. Screening for prostate cancer. N Engl J Med 2011;365:2013-2019.
6.
Foulkes WD: Inherited susceptibility to common cancers. N Engl J Med 2008;359:2143-2153.
7.
Dong LM, Potter JD, White E, et al: Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 2008;299:2423-2436.
8.
Hayes JD, Flanagan JU, Jowsey IR: Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88.
9.
Sharma R, Yang Y, Sharma A, et al: Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis. Antioxid Redox Signal 2004;6:289-300.
10.
Strange RC, Spiteri MA, Ramachandran S, et al: Glutathione S-transferase family of enzymes. Mutat Res 2001;482:21-26.
11.
Hayes JD, Strange RC: Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000;61:154-166.
12.
Webb G, Vaska V, Coggan M, et al: Chromosomal localization of the gene for the human theta class glutathione transferase (GSTT1). Genomics 1996;33:121-123.
13.
Rodrigues IS, Kuasne H, Losi-Guembarovski R, et al: Evaluation of the influence of polymorphic variants CYP1A1 2b, CYP1B1 2, CYP3A4 1b, GSTM1 0, and GSTT1 0 in prostate cancer. Urol Oncol 2011;29:654-663.
14.
Safarinejad MR, Shafiei N, Safarinejad SH: Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and prostate cancer: a case-control study in Tehran, Iran. Prostate Cancer Prostatic Dis 2011;14:105-113.
15.
Beer TM, Evans AJ, Hough KM, et al: Polymorphisms of GSTP1 and related genes and prostate cancer risk. Prostate Cancer Prostatic Dis 2002;5:22-27.
16.
Norskov MS, Frikke-Schmidt R, Bojesen SE, et al: Copy number variation in glutathione S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population. Pharmacogenomics J 2011;11:292-299.
17.
Autrup JL, Thomassen LH, Olsen JH, et al: Glutathione S-transferases as risk factors in prostate cancer. Eur J Cancer Prev 1999;8:525-532.
18.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
19.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
20.
Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
21.
Cochran WG: The combination of estimates from different experiments. Biometrics 1954;10:101-129.
22.
Lau J, Antman EM, Jimenez-Silva J, et al: Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-254.
23.
Ioannidis JP, Boffetta P, Little J, et al: Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008;37:120-132.
24.
Galbraith R: A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889-894.
25.
Tobias A: Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999;8:15-17.
26.
Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
27.
Davydova NA, Dmitrieva AI, Selivanov SP, et al: Polymorphism of glutathione S-transferase genes in patients with prostatic cancer (in Russian). Urologiia 2008;2:26-29.
28.
Medeiros R, Vasconcelos A, Costa S, et al: Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate 2004;58:414-420.
29.
Lindstrom S, Zheng SL, Wiklund F, et al: Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006;66:1729-1743.
30.
Kote-Jarai Z, Easton D, Edwards SM, et al: Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics 2001;11:325-330.
31.
Joseph MA, Moysich KB, Freudenheim JL, et al: Cruciferous vegetables, genetic polymorphisms in glutathione S-transferases M1 and T1, and prostate cancer risk. Nutr Cancer 2004;50:206-213.
32.
Sivonova M, Waczulikova I, Dobrota D, et al: Polymorphisms of glutathione S-transferase M1, T1, P1 and the risk of prostate cancer: a case-control study. J Exp Clin Cancer Res 2009;28:32.
33.
Lima MM Jr, Oliveira MN, Granja F, et al: Lack of association of GSTT1, GSTM1, GSTO1, GSTP1 and CYP1A1 polymorphisms for susceptibility and outcome in Brazilian prostate cancer patients. Folia Biol (Praha) 2008;54:102-108.
34.
Silig Y, Pinarbasi H, Gunes S, et al: Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest 2006;24:41-45.
35.
Steinbrecher A, Rohrmann S, Timofeeva M, et al: Dietary glucosinolate intake, polymorphisms in selected biotransformation enzymes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010;19:135-143.
36.
Souiden Y, Mahdouani M, Chaieb K, et al: Polymorphisms of glutathione S-transferase M1 and T1 and prostate cancer risk in a Tunisian population. Cancer Epidemiol 2010;34:598-603.
37.
Steinhoff C, Franke KH, Golka K, et al: Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol 2000;74:521-526.
38.
Xu D, Yan S, Yin J, et al: Null genotype of GSTT1 contributes to colorectal cancer risk in Asian populations: evidence from a meta-analysis. Asian Pac J Cancer Prev 2011;12:2279-2284.
39.
Chen XX, Zhao RP, Qiu LX, et al: Glutathione S-transferase T1 polymorphism is associated with breast cancer susceptibility. Cytokine 2011;56:477-480.
40.
Ye Z, Song H, Higgins JP, et al: Five glutathione S-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies. PLoS Med 2006;3:e91.
41.
Wang B, Huang G, Wang D, et al: Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol 2010;53:508-518.
42.
Ioannidis JP, Patsopoulos NA, Evangelou E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007;335:914-916.
43.
Mo Z, Gao Y, Cao Y, et al: An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a huge review. Prostate 2009;69:662-688.
44.
Ntais C, Polycarpou A, Ioannidis JP: Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005;14:176-181.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
